These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39386278)

  • 41. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
    Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Epidemiology of SARS-CoV-2 Omicron Sub-Lineages Isolated from Turkish Patients Infected with COVID-19.
    Sayan M; Arikan A; Sanlidag E
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A yeast-based system to study SARS-CoV-2 M
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of
    Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Wastewater Genomic Surveillance Captures Early Detection of Omicron in Utah.
    Gupta P; Liao S; Ezekiel M; Novak N; Rossi A; LaCross N; Oakeson K; Rohrwasser A
    Microbiol Spectr; 2023 Jun; 11(3):e0039123. PubMed ID: 37154725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
    Yang KS; Leeuwon SZ; Xu S; Liu WR
    J Med Chem; 2022 Jul; 65(13):8686-8698. PubMed ID: 35731933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SARS-CoV-2 3CL
    Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
    Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.
    Rosales R; McGovern BL; Rodriguez ML; Leiva-Rebollo R; Diaz-Tapia R; Benjamin J; Rai DK; Cardin RD; Anderson AS; ; Sordillo EM; van Bakel H; Simon V; García-Sastre A; White KM
    Antiviral Res; 2024 Oct; 230():105970. PubMed ID: 39067667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19.
    Navitha Reddy G; Jogvanshi A; Naikwadi S; Sonti R
    Expert Rev Anti Infect Ther; 2023; 21(9):943-955. PubMed ID: 37525997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutational Patterns Observed in SARS-CoV-2 Genomes Sampled From Successive Epochs Delimited by Major Public Health Events in Ontario, Canada: Genomic Surveillance Study.
    Chen D; Randhawa GS; Soltysiak MP; de Souza CP; Kari L; Singh SM; Hill KA
    JMIR Bioinform Biotechnol; 2022 Dec; 3(1):e42243. PubMed ID: 38935965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.
    Zhu Y; Yurgelonis I; Noell S; Yang Q; Guan S; Li Z; Hao L; Rothan H; Rai DK; McMonagle P; Baniecki ML; Greasley SE; Plotnikova O; Lee J; Nicki JA; Ferre R; Byrnes LJ; Liu W; Craig TK; Steppan CM; Liberator P; Soares HD; Allerton CMN; Anderson AS; Cardin RD
    Sci Adv; 2024 Jul; 10(30):eadl4013. PubMed ID: 39047088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    Res Sq; 2022 Aug; ():. PubMed ID: 36052369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
    Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
    Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.